Testing two drug plans for HER2 positive breast cancer that has spread to the brain
Official title: T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This trial asks if adding a second drug helps when HER2 positive breast cancer reaches the brain.
Read our full plain-language summary
What the trial team says
A phase II, open-label, multicenter, randomized controlled trial exploring the efficacy and safety of Trastuzumab Deruxtecan combined with or without Neratinib in HER2-positive breast cancer with brain metastasis
Key facts
- Registry number
- NCT07152782
- Stage of testing
- Phase 2
- Conditions studied
- Breast Cancer With Brain Metastasis, HER2-positive Breast Cancer
Where it is running
This trial lists 1 site.
-
China
- Fudan University Shanghai Cancer Center (Shanghai)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.